0001662244false00016622442023-11-292023-11-2900016622442023-10-032023-10-03

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 29, 2023

 

 

Cyteir Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-40499

45-5429901

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

99 Hayden Street, Building B, Suite 450

 

Lexington, Massachusetts

 

02421

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 857 285-4140

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.001 par value per share

 

CYT

 

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On November 29, 2023, in connection with the previously announced planned liquidation and dissolution of the Company, Jeffrey Humphrey, M.D., notified the board of directors of Cyteir Therapeutics, Inc. (the “Company”) of his resignation from the board of directors and all of its committees, effective immediately. The resignation is not a result of any disagreement between Dr. Humphrey and the Company.

 

On December 4, 2023, Racquel Bracken also notified the board of directors of the Company of her resignation from the board of directors and all of its committees, effective immediately. The resignation is not a result of any disagreement between Ms. Bracken and the Company.

 

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

CYTEIR THERAPEUTICS, INC.

 

 

 

 

Date:

December 5, 2023

By:

/s/ David Gaiero

 

 

 

Name: David Gaiero
Title: Chief Financial Officer and Treasurer

 

v3.23.3
Document and Entity Information
Nov. 29, 2023
Oct. 03, 2023
Cover [Abstract]    
Amendment Flag   false
Entity Central Index Key   0001662244
Document Type   8-K
Document Period End Date Nov. 29, 2023  
Entity Registrant Name   Cyteir Therapeutics, Inc.
Entity Incorporation State Country Code   DE
Securities Act File Number   001-40499
Entity Tax Identification Number   45-5429901
Entity Address, Address Line One   99 Hayden Street, Building B
Entity Address, Address Line Two   Suite 450
Entity Address, City or Town   Lexington
Entity Address, State or Province   MA
Entity Address, Postal Zip Code   02421
City Area Code   857
Local Phone Number   285-4140
Written Communications   false
Soliciting Material   false
Pre Commencement Tender Offer   false
Pre Commencement Issuer Tender Offer   false
Security 12b Title   Common Stock, $0.001 par value per share
Trading Symbol   CYT
Security Exchange Name   NASDAQ
Entity Emerging Growth Company   true
Entity Ex Transition Period   false
Cyteir Therapeutics (NASDAQ:CYT)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Cyteir Therapeutics Charts.
Cyteir Therapeutics (NASDAQ:CYT)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Cyteir Therapeutics Charts.